355 related articles for article (PubMed ID: 28363320)
1. The Prescription Opioid Addiction Treatment Study: What have we learned.
Weiss RD; Rao V
Drug Alcohol Depend; 2017 Apr; 173 Suppl 1(Suppl 1):S48-S54. PubMed ID: 28363320
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study.
Weiss RD; Potter JS; Griffin ML; Provost SE; Fitzmaurice GM; McDermott KA; Srisarajivakul EN; Dodd DR; Dreifuss JA; McHugh RK; Carroll KM
Drug Alcohol Depend; 2015 May; 150():112-9. PubMed ID: 25818060
[TBL] [Abstract][Full Text] [Related]
3. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.
McDermott KA; Griffin ML; Connery HS; Hilario EY; Fiellin DA; Fitzmaurice GM; Weiss RD
J Clin Psychiatry; 2015 Feb; 76(2):189-94. PubMed ID: 25562462
[TBL] [Abstract][Full Text] [Related]
4. The multi-site prescription opioid addiction treatment study: 18-month outcomes.
Potter JS; Dreifuss JA; Marino EN; Provost SE; Dodd DR; Rice LS; Fitzmaurice GM; Griffin ML; Weiss RD
J Subst Abuse Treat; 2015 Jan; 48(1):62-9. PubMed ID: 25189089
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders.
Romero-Gonzalez M; Shahanaghi A; DiGirolamo GJ; Gonzalez G
Am J Addict; 2017 Dec; 26(8):838-844. PubMed ID: 29143399
[TBL] [Abstract][Full Text] [Related]
6. Short term health-related quality of life improvement during opioid agonist treatment.
Nosyk B; Bray JW; Wittenberg E; Aden B; Eggman AA; Weiss RD; Potter J; Ang A; Hser YI; Ling W; Schackman BR
Drug Alcohol Depend; 2015 Dec; 157():121-8. PubMed ID: 26511766
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
[TBL] [Abstract][Full Text] [Related]
8. Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain.
Worley MJ; Heinzerling KG; Shoptaw S; Ling W
Exp Clin Psychopharmacol; 2015 Dec; 23(6):428-35. PubMed ID: 26302337
[TBL] [Abstract][Full Text] [Related]
9. Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.
Dreifuss JA; Griffin ML; Frost K; Fitzmaurice GM; Potter JS; Fiellin DA; Selzer J; Hatch-Maillette M; Sonne SC; Weiss RD
Drug Alcohol Depend; 2013 Jul; 131(1-2):112-8. PubMed ID: 23333292
[TBL] [Abstract][Full Text] [Related]
10. Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?
Weiss RD; Griffin ML; Potter JS; Dodd DR; Dreifuss JA; Connery HS; Carroll KM
Drug Alcohol Depend; 2014 Jul; 140():118-22. PubMed ID: 24831754
[TBL] [Abstract][Full Text] [Related]
11. Correlates of Opioid Abstinence in a 42-Month Posttreatment Naturalistic Follow-Up Study of Prescription Opioid Dependence.
Weiss RD; Griffin ML; Marcovitz DE; Hilton BT; Fitzmaurice GM; McHugh RK; Carroll KM
J Clin Psychiatry; 2019 Mar; 80(2):. PubMed ID: 30920187
[TBL] [Abstract][Full Text] [Related]
12. Using behavioral economics to predict opioid use during prescription opioid dependence treatment.
Worley MJ; Shoptaw SJ; Bickel WK; Ling W
Drug Alcohol Depend; 2015 Mar; 148():62-8. PubMed ID: 25622776
[TBL] [Abstract][Full Text] [Related]
13. A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology.
Weiss RD; Potter JS; Provost SE; Huang Z; Jacobs P; Hasson A; Lindblad R; Connery HS; Prather K; Ling W
Contemp Clin Trials; 2010 Mar; 31(2):189-99. PubMed ID: 20116457
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal association between pain severity and subsequent opioid use in prescription opioid dependent patients with chronic pain.
Griffin ML; McDermott KA; McHugh RK; Fitzmaurice GM; Jamison RN; Weiss RD
Drug Alcohol Depend; 2016 Jun; 163():216-21. PubMed ID: 27161860
[TBL] [Abstract][Full Text] [Related]
15. Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.
Mokri A; Chawarski MC; Taherinakhost H; Schottenfeld RS
Addiction; 2016 May; 111(5):874-82. PubMed ID: 26639678
[TBL] [Abstract][Full Text] [Related]
16. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
[TBL] [Abstract][Full Text] [Related]
17. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
[TBL] [Abstract][Full Text] [Related]
18. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users.
Nielsen S; Hillhouse M; Mooney L; Ang A; Ling W
J Subst Abuse Treat; 2015 Jan; 48(1):70-6. PubMed ID: 25065489
[TBL] [Abstract][Full Text] [Related]
20. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.
Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M
Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
